Author

Maya Stefanova-Urena

Observed institution: Sanofi (United States)

OpenAlex ID: A5099177440

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

2025 · Sikander Ailawadhi, Ivan Špička, et al. · Journal of Clinical Oncology · 22

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5

2024 · Javier Cortés, Sara A. Hurvitz, et al. · Journal of Clinical Oncology · 22

Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)

2025 · María-Victoria Mateos, Ivan Špička, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Isatuximab subcutaneous in relapsed/refractory multiple myeloma: Exposure-response and serum m-protein dynamics analyses from phase 3 iraklia Study and the phase 1b Study

2025 · Nadia Gaudel, Hoai-Thu Thai, et al. · Blood · 1

Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study

2025 · Sikander Ailawadhi, Ivan Špička, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

2025 · Sikander Ailawadhi, Ivan Špička, et al. · Journal of Clinical Oncology · 1

Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.

2025 · Sikander Ailawadhi, Ivan Spicka, et al. · Journal of Clinical Oncology · 1

PA-363 Premedication Use and Infusion-Related Reactions in Patients Treated With Subcutaneous Isatuximab: A Pooled Post Hoc Safety Analysis

2026 · Fredrik Schjesvold, Alejandro Berkovits, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-432 Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials

2026 · Xavier Leleu, Claudio Cerchione, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-271 Isatuximab Plus Pomalidomide-Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Subgroup Analysis by Prior Anti-CD38 Exposure From the Phase 3 IRAKLIA Trial

2026 · Albert Oriol, Marek Hus, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-518 Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Patients With Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study

2026 · Sikander Ailawadhi, Fredrik Schjesvold, et al. · Clinical Lymphoma Myeloma & Leukemia

MM-754: Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials

2026 · Xavier Leleu, Claudio Cerchione, et al. · Clinical Lymphoma Myeloma & Leukemia

MM-609: Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study

2026 · Sikander Ailawadhi, Fredrik Schjesvold, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: MM-754: Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials

2026 · Xavier Leleu, Claudio Cerchione, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: MM-609: Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study

2026 · Sikander Ailawadhi, Fredrik Schjesvold, et al. · Clinical Lymphoma Myeloma & Leukemia

Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.

2026 · Xavier P. Leleu, Claudio Cerchione, et al. · Journal of Clinical Oncology

Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.

2026 · Albert Oriol Rocafiguera, Marek Hus, et al. · Journal of Clinical Oncology

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

2025 · Jin Lu, Albert Oriol, et al. · Blood

Isatuximab Subcutaneous via an On-Body Injector Plus Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma: Subgroup Analysis by Prior Lines of Therapy from the Phase 3 IRAKLIA Trial

2025 · Claudio Cerchione, Sikander Ailawadhi, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 19

Citation count: 50

H-index: 2

I10-index: 2